Teva Pharmaceutical Industries Ltd (ADR) TEVA won't attract rivals for its $3.2 billion bid for Auspex Pharmaceuticals Inc ASPX, an analyst said Tuesday.
Stifel's Stephen Willey downgraded Auspex to Hold and called its acquisition, at $101 a share, "a great strategic fit" for Israel-based Teva.
Auspex traded recently at $100.32, off $0.04; Teva changed hands at $63.19, up $0.67.
The companies announced the all-cash deal Monday and said the transaction, expected to close mid-year, has support of both company's boards and key Auspex shareholders.
Willey said Teva valued Auspex solely on expected sales of its SD-809 drug, for which it plans a commercial launch as a treatment for Huntington's disease next year.
The drug also has potential as a treatment for tardive dyskenesia, the involuntary body movements which are a frequent side-effect of anti-psychotic drugs. Studies on the drug are also underway as a potential treatment for Tourette's syndrome.
Teva expects the drug could provide peak annual sales of $2 billion, suggesting its acquisition of Auspex is "a bargain," Willey said.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in